Bryce A. Harrison, Framingham, MA (US); James E. Dowling, Lexington, MA (US); Matthew G. Bursavich, Needham, MA (US); Dawn M. Troast, Bedford, MA (US); Blaise S. Lippa, Newton, MA (US); Bruce N. Rogers, Belmont, MA (US); Kristopher N. Hahn, Medford, MA (US); Cheng Zhong, Belmont, MA (US); Qi Qiao, Natick, MA (US); Fu-Yang Lin, Sudbury, MA (US); Brian Sosa, Cambridge, MA (US); Aleksey I. Gerasyuto, Flemington, NJ (US); Andrea Bortolato, Metuchen, NJ (US); Mats A. Svensson, New York, NY (US); Eugene Hickey, Danbury, CT (US); Kyle D. Konze, Katonah, NY (US); Tyler Day, New York, NY (US); and Byungchan Kim, West New York, NJ (US)
Assigned to Morphic Therapeutic, Inc., Waltham, MA (US)
Filed by Morphic Therapeutic, Inc., Waltham, MA (US)
Filed on Jan. 8, 2024, as Appl. No. 18/406,817.
Application 18/406,817 is a continuation of application No. 18/226,497, filed on Jul. 26, 2023, abandoned.
Application 18/226,497 is a continuation of application No. 17/239,045, filed on Apr. 23, 2021, granted, now 11,739,087, issued on Aug. 29, 2023.
Application 17/239,045 is a continuation of application No. 17/001,086, filed on Aug. 24, 2020, granted, now 11,021,480, issued on Jun. 1, 2021.
Application 17/001,086 is a continuation of application No. 16/555,589, filed on Aug. 29, 2019, abandoned.
Claims priority of provisional application 62/859,457, filed on Jun. 10, 2019.
Claims priority of provisional application 62/724,423, filed on Aug. 29, 2018.
Prior Publication US 2024/0376095 A1, Nov. 14, 2024
